showed that mutations in Janus kinase 1 (JAK1), JAK2, and B2M in tumor samples after immunotherapy may be the mechanisms of acquired resistance to anti-PD-L1 therapy in melanoma patients (122). This evidence concerns the gene B2M and neoplasm.